← Back to patent-cliff list
LNK-01003
Tier C — Watch / tradeLNK-01003
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Protein kinases
Indications (approved)：Ulcerative colitis, Inflammatory bowel disease
Regional status
US
-
EU
-
China
Phase II
2022-11-25
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of LNK-01003?
Approved indications include: Ulcerative colitis, Inflammatory bowel disease.
When does the LNK-01003 patent expire?
No public expiry year is available for LNK-01003 yet; this page updates once verified.
How do I get a quote for LNK-01003 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03